FORMULATION AND EVALUATION OF SUSTAINED RELEASE TABLET OF MIGLITOL
Monika Chauhan*, Anshul Jain and Satyaveer Singh, Kuldeep Chaurasiya
ABSTRACT
The purpose of the present study was to develop sustained release tablets of Miglitol, an oral alpha-glucosidase inhibitor for use in the management of non-insulin-dependent diabetes mellitus (NIDDM), an anti-diabetic drug which are designed for better management of diabetes mellitus to minimize side effects, to improve patient compliance and preventing the fluctuation of therapeutic concentration of the drug in the body.The Miglitol sustained release tablets (F1 – F10) were prepared by direct compression method using HPMC K4,K15,K100 polymers in different ratios.. Granules were performed by Preformulation studies. The Miglitol sustained release tablets were
evaluated for hardness, friability, weight variation, drug content and In-vitro dissolution study. The Miglitol sustained release tablets showed drug release from 18.42 to 96,6% of drug at the end of 12th hr by in-vitro dissolution study. The formulation F8 was selected as an optimized formulation because it gives the best result in terms of drug release in sustained release manner. The kinetic release treatment showed that the release of drug follows zero order kinetic (R2 value as 0.997), korsemeyer equation gave value of (R2= 0.879) which was close to one indicating that the drug was released by zero order kinetic and Short term stability studies indicated that there is no appreciable changes in the drug content and in vitro drug release rates of optimized formulation F8.
Keywords: Miglitol, HPMC K4, K15, K100, Direct compression Method, Sustained Release.
[Download Article]
[Download Certifiate]